<DOC>
	<DOCNO>NCT00220831</DOCNO>
	<brief_summary>The purpose study determine whether Vitamin E treatment Diabetic patient , carry Haptoglobin 2-2 Phenotype , prevent cardiovascular complication acute MI Stroke .</brief_summary>
	<brief_title>Prevention Cardiovascular Complications Diabetic Patients With Vitamin E Treatment</brief_title>
	<detailed_description>Haptoglobin free Hemoglobin scavenger protein . Hemoglobin oxidant due Fe carry Fenton reaction . Thus believe Haptoglobin antioxidant , especially site vascular injury . Haptoglobin three phenotype easily identify method gel electrophoresis . The three phenotype denote 1-1 , 2-1 2-2 . We find several vitro study lab Haptoglobin 1-1 superior antioxidant 2-2 . In several large retrospective study find Diabetic patient Haptoglobin type 2-2 5 time risk cardiovascular complication ( acute MI , CVA , CVD death ) one Haptoglobin 1-1 . 2-1 patient probably intermediate risk . While retrospectively type consecutive serum patient participate HOPE study find take Vitamin E decrease 50 % CVD incidences Diabetic patient Haptoglobin 2-2 phenotype . Based finding wish perform I CARE study . 5000 diabetic patient age 55 , test Haptoglobin phenotype . Knowing distribution different Haptoglobin phenotype Israeli population estimate 2000 phenotype 2-2 . These 2000 patient enrol prospective , double blind , randomize placebo control clinical study randomly divide 2 group , one receiving Vitamin E 400IU per day receive match placebo . All patient follow routinely primary physician Clalit HMO ( big HMO Israel ) routine diabetes follow treatment ( HbA1c , blood pressure control , Lipids , renal function , eye exam retinopathy etc… ) The study steer committee get anamnestic data routine test result every 3 month . Primary Outcomes : combination CVD mortality non fatal MI Stroke . Secondary Outcomes : Cardiac Interventions ( Angioplasty , Bypass surgery etc… ) , cause mortality , heart failure . Exclusion criterion : 1 ) patient take antioxidant treatment ask stop , ca n't include study . 2 ) Patients CVD incident ( MI , Stroke , TIA ) , Unstable angina pectoris , Uncontrolled HTN , wait month stabilization include study . 3 ) Allergy Vitamin E. Follow duration – 4.5 year . 5 % percent vitamin receiver test base line year enrollment , Vitamin E plasma concentration .</detailed_description>
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin E</mesh_term>
	<mesh_term>Tocopherols</mesh_term>
	<mesh_term>Tocotrienols</mesh_term>
	<mesh_term>alpha-Tocopherol</mesh_term>
	<criteria>Diabetic patient age 55 Patient take antioxidant treatment ask stop , ca n't include study Patients CVD incident ( MI , Stroke , TIA ) , Unstable angina pectoris , Uncontrolled HTN , wait month stabilization include study Allergy Vitamin E</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2007</verification_date>
	<keyword>Diabetes</keyword>
	<keyword>MI</keyword>
	<keyword>CVD disease</keyword>
</DOC>